CRA provided expert reports and testimony on behalf of the respondent in an AAA arbitration concerning the “fair market value” of rights exchanged in later agreements made by the licensee. At issue was whether the subsequent transfer and reorganization of such rights would trigger a “payment” under the terms of the original collaboration and license agreement. CRA provided context for drug development and collaboration agreements in the pharmaceutical industry. In addition, CRA reviewed Claimant’s damages claims and provided opinions as to whether it properly constituted an estimate of “fair market value” of rights to future sales of drugs that had not reached the market.
Representations and warranties insurance
Insurance for mergers and acquisitions has grown significantly over the last several years as it allows buyers and sellers to share the transaction risk with a...